 20-Feb-18, China Money Network

Fosun International and London-based healthcare and life science company Arix Bioscience have announced a strategic agreement to develop and commercialize new clinical therapies for patients with a focus on the Chinese markets.

Image: China Money Network

As part of the agreement, Arix and Fosun will collaborate to invest in and create new companies focused on the development of innovative clinical therapies across a broad range of therapeutic areas, with a particular emphasis on the Chinese market.

Arix will provide Fosun with access to its group businesses, pipeline and network of key professional and scientific advisors. In turn, Fosun will share potential investment opportunities in China and will have the opportunity to promote its services as exclusive distribution partner in China for Arix’s Group Businesses.

 Read the full article  

 Healthcare insights